Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Salicylic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.53 |
| ▸ | CA2 | P00918 | 7/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Salicylic Acid SCHEMBL4189986 | 0.79 | ALDH1A1 (0.78) | CA1CA2ALDH1A1KDM4EHPGD | |
| Terephthalic Acid SCHEMBL29162965 | 0.78 | TP53 (0.43) | CA1CA2ALDH1A1CA12SMN1; SMN2 | |
| SCHEMBL5348734 | 0.77 | TSHR (0.45) | CA1CA2ALDH1A1KDM4EHPGD | |
| Salicylic Acid SCHEMBL28234101 | 0.77 | ALDH1A1 (0.82) | CA1CA2ALDH1A1KDM4EHPGD | |
| Salicylic Acid SCHEMBL5874171 | 0.77 | ALDH1A1 (0.82) | CA1CA2ALDH1A1KDM4EHPGD | |
| Creatine SCHEMBL30063981 | 0.77 | — | — | |
| Creatine SCHEMBL27979093 | 0.77 | NOS3 (0.46) | CA1CA2 | |
| Creatine SCHEMBL21567 | 0.77 | — | — | |
| Creatine SCHEMBL4007614 | 0.77 | NOS3 (0.46) | CA1CA2 | |
| Salicylic Acid SCHEMBL5693247 | 0.75 | ALDH1A1 (0.78) | CA1CA2ALDH1A1KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | claimed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | claimed |
| US-7179477-B2 | Cosmetic dermabrasion treatment system | GUPTA SHYAM K | 2007-02-20 | — | — | US | disclosed |
| WO-2006023710-A2 | COSMETIC OR PHARMACEUTICAL COMPOSITION FOR SKIN CARE | INFINITY2 HEALTH SCIENCES, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
| US-20060039887-A1 | Cosmetic or pharmaceutical composition for skin care | INFINITY2 HEALTH SCIENCES, INC. | 2006-02-23 | — | — | US | disclosed |
| US-20050037038-A1 | Cosmetic Dermabrasion Treatment System | GUPTA SHYAM K (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | disclosed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | CUTA, HIRA, HARS1 | CA1 4564/4885CA2 2536/4885ALDH1A1 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.